|
|
Blood, 15 August 2007, Vol. 110, No. 4, pp. 1233-1237.
Prepublished online as a Blood First Edition Paper on April 20, 2007; DOI 10.1182/blood-2007-01-070144.
 Previous Article | Next Article 
Submitted January 25, 2007
Accepted April 17, 2007
Congestive heart failure is a rare event in patients receiving imatinib therapy
Ehab Atallah, Jean-Bernard Durand, Hagop M Kantarjian, and Jorge Cortes*
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Department of Cardiology, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
* Corresponding author; email: jcortes{at}mdanderson.org.
A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We reviewed all reported serious adverse events of cardiac adverse events occurring in patients on clinical trials involving imatinib. Among 1276 patients enrolled, 22 (1.8%) were identified as having symptoms that could be attributed to systolic heart failure. The median age was 70 yrs (range, 49 to 83 yrs). The median time from start of imatinib therapy was 162 days (2-2045 days). At the time these events were reported, 8 (0.6%) were considered possibly or probably related to imatinib. Eighteen patients had previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF) (6 patients, 27%), diabetes mellitus (6 patients, 27%), hypertension (10 patients, 45%), coronary artery disease (CAD) (8 patients, 36%), arrhythmia (3 patients, 14%) and cardiomyopathy (1 pt 5%). Eleven of the 22 patients continued imatinib therapy with dose adjustments and management for the CHF symptoms without further complications. Imatinib therapy as a causal factor of CHF is uncommon, mainly seen in elderly patients with pre-existing cardiac conditions. Patients with previous cardiac history should be monitored closely and treated aggressively with standard medical therapy including diuretics if they develop symptoms suggestive of heart failure.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C. Wang, S. M. Davies, P. S. Gaynon, M. Trigg, et al.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
November 1, 2009;
27(31):
5175 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Raj, C. M. Stein, P. J. Saavedra, and D. M. Roden
Cardiovascular Effects of Noncardiovascular Drugs
Circulation,
September 22, 2009;
120(12):
1123 - 1132.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol.,
June 16, 2009;
53(24):
2231 - 2247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine,
April 1, 2009;
26(2):
137 - 146.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Souza and C. Jardim
Trends in pulmonary arterial hypertension
Eur. Respir. Rev.,
March 1, 2009;
18(111):
7 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Telli, R. M. Witteles, G. A. Fisher, and S. Srinivas
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Ann. Onc.,
September 1, 2008;
19(9):
1613 - 1618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Chen, R. Kerkela, and T. Force
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Circulation,
July 1, 2008;
118(1):
84 - 95.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med.,
March 15, 2008;
177(6):
574 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment
Blood,
February 1, 2008;
111(3):
1039 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
